On Nov 06, major Wall Street analysts update their ratings for $Bruker Corp (BRKR.US)$, with price targets ranging from $69 to $80.
J.P. Morgan analyst Rachel Vatnsdal maintains with a buy rating, and adjusts the target price from $90 to $80.
BofA Securities analyst Michael Ryskin maintains with a buy rating, and sets the target price at $78.
Citi analyst Patrick B Donnelly maintains with a buy rating, and adjusts the target price from $80 to $75.
Barclays analyst Luke Sergott maintains with a buy rating, and adjusts the target price from $75 to $69.
Wells Fargo analyst Brandon Couillard maintains with a buy rating, and maintains the target price at $75.
Furthermore, according to the comprehensive report, the opinions of $Bruker Corp (BRKR.US)$'s main analysts recently are as follows:
Bruker experienced continued softness in the China market and within the biopharma sector during the quarter, according to an analyst.
The company faced a challenging earnings report amidst a difficult macroeconomic climate. Adjustments to forecasts are being made in light of revised fiscal 2024 targets. Despite the adjustments, there is optimism that the company's strong positioning in multi-omics and materials sciences will enable it to capitalize on the anticipated demand resurgence in the biopharma sector and Chinese market.
Bruker's Q3 outcomes fell short of expectations, and the company has reduced its projections for organic sales growth for fiscal 2024, attributing this adjustment to a slower rebound in China and emerging biopharma sectors. According to the analyst, this recalibration of guidance was not caused by a significant downturn in Q3 markets, but rather by previously optimistic forecasts. Despite the revised guidance, the company's management remains optimistic about prospects for 2025.
The company reported a miss for Q3, but the observed trends in BSI Bookings and the updated guidance could improve the outlook as the company heads into Q4.
The positive aspect of the revised guidance for the second half of the year is that it sets the stage for a recalibration of expectations for 2025, potentially lifting a burden for investors.
Here are the latest investment ratings and price targets for $Bruker Corp (BRKR.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
